Alexandra Balcom

NUVL CFO Alexandra Balcom sells 11,430 shares across 8 transactions for $1,128,080.49 via pre-arranged plan.

Alexandra Balcom, CFO of Nuvalent, executed 8 separate sales totaling 11,430 shares for $1,128,080.49 on 2026-06-01, reducing her non-derivative holdings from 96,963 to 85,533 shares. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-23, making it scheduled rather than discretionary. The blended average sale price of $98.69 compares to a current price of $90.18, with the stock down 20.2% from its 52-week high of $113.02 and down 12.1% over the past 30 days. Balcom retains 13,400 stock options and significant non-derivative holdings post-transaction, so her overall position remains material. The company's unprofitable status (net income of $-109,279,000.00) and recent negative momentum warrant attention to whether subsequent earnings or operational updates clarify the outlook.

CFO Balcom exercises vested options, immediately trims full position at elevated prices amid unprofitable financials.

CFO Alexandra Balcom exercised vested stock options and simultaneously sold all acquired shares—a classic liquidity harvest with zero net position change. The sale was executed at prices well above the exercise cost, netting over $1.1 million. However, this trade takes place within a company still burning cash with mounting losses, and the stock is trading meaningfully below its 52-week high, suggesting the CFO chose this window to monetize rather than hold. Balcom's prior sales at this stock have shown mixed timing: three of five previous exits were followed by stock declines (well-timed exits), while two saw subsequent rallies. This current sale—timed at prices near the 52-week high—follows her established pattern as a net seller and represents the sixth through eighth open-market sale at Nuvalent in the past three years. The structure itself (exercise-and-sell) is routine and reflects vesting schedules more than conviction, but the scale and context matter: a CFO liquidating her full position while the company posts consistent quarterly losses is a form of confidence exit that deserves attention.

CFO Balcom sells 11,430 shares at $104.39–$106.18 for $1,202,526.68; retains 85,533 shares

Balcom Alexandra, Chief Financial Officer, executed 3 separate sales on 2026-04-01 totaling 11,430 shares for $1,202,526.68, reducing her holdings from 96,963 shares to 85,533 shares. The blended average price of $105.21 sits just below the current price of $105.43, placing the transaction near contemporaneous market levels; the stock trades -5.9% from its 52-week high of $111.99. At Nuvalent specifically, Balcom has completed 5 prior trades (4 sales on 2026-03-24 and 2026-03-25, 1 sale on 2026-01-06), with the January sale showing a +4.3% 30-day return and no measurable 90-day outcome yet; 0 of 0 prior same-ticker sales have demonstrated well-timed exit patterns at the 90-day mark. Nuvalent reported a full-year net income of -$122,437,000, indicating ongoing unprofitability. The sale represents an 11.8% reduction in her pre-transaction holdings, a material but not dominant step down in position size.

CFO Balcom sold 25,130 shares of NUVL across 4 transactions for $2,466,610.45; stock now at $98.06, down 12.4% from 52-week high.

Balcom Alexandra, Chief Financial Officer of Nuvalent, Inc., executed 4 separate sales totaling 25,130 shares for $2,466,610.45 on March 24–25, 2026, reducing her holdings by 22.7% from 110,663 to 85,533 shares. The blended average sale price across the four transactions was $98.15, only $0.09 above the current market price of $98.06, suggesting the sales executed near current market levels rather than at a significant discount. Nuvalent remains unprofitable with a net loss of $122,437,000 for its most recent full fiscal year and a market cap of $306,867,395.04; the stock is currently 12.4% below its 52-week high and has declined 6.6% over the past 30 days. Her cross-ticker track record shows a 90-day well-timed sell rate of 53.85%, though her 5 prior same-ticker sells at NUVL posted strong 30-day returns (ranging from +2.5% to +9.3%) with no yet-measurable 90-day outcomes, providing limited directional guidance for this filing.

CFO Balcom sold 7,417 shares for $721,320.39 across Jan 5-6; stock at $106.82 vs 52-week high $109.86.

Balcom Alexandra, the CFO of unprofitable Nuvalent, executed 7 separate sales totaling 7,417 shares for $721,320.39 at an average price of $97.25 on January 5–6, 2026. Her post-transaction holdings of 99,233 shares represent a 7.0% reduction from the prior 106,650 shares. The stock currently trades at $106.82, near its 52-week high of $109.86, and has appreciated 21.4% over the past 90 days. Her cross-ticker track record across 20 prior sells shows an average 90-day return of +17.8% (with a 0.00% well-timed rate), but her same-ticker history at NUVL—5 prior sells—shows mixed 30-day outcomes (-3.2%, -4.0%, -3.0%, -2.1%, +7.9%), with none yet measurable at the 90-day horizon. The sale occurred in the context of substantial unrealized gains and positive recent momentum, yet the company remains deeply unprofitable ($-122.4M net loss over the most recent full fiscal year) on a market cap of $334.3M.

CFO Balcom sells 7.1K shares of NUVL for $781.5K; stock up 13.7% in 30 days post-sale but company remains deeply unprofitable.

Balcom Alexandra, Chief Financial Officer, executed 2 separate sales totaling 7,084 shares for $781,537.04 on 2025-12-08, at a blended average price of $110.32. This represents an 11.5% reduction in her holdings, bringing her position to 54,650 shares post-transaction. The sale occurred as NUVL trades near its 52-week high ($109.86 range) and the stock has rallied 13.7% over the prior 30 days and 28.6% over 90 days—suggesting the sale was executed into recent strength. However, the timing context is mixed: Balcom's cross-ticker track record shows a 90-day well-timed rate of 100%, though her 5 most recent same-ticker trades at NUVL (all in November 2025) have not yet matured to measurable 90-day outcomes. The material concern is the company's fundamentals: Nuvalent reported a net loss of $122.4M over its most recent fiscal year with a market cap of only $330.9M, indicating the company is burning cash at a rate that exceeds its entire market value. An investor should monitor whether this CFO-level sale signals internal caution about sustainability, particularly given the company's severe unprofitability.

CFO Balcom Alexandra sold 20,729 shares at $93.80–$104.54 for $2,065,030.33 on 2025-11-17 to -11-18 (25.1% portfolio reduction).

Alexandra Balcom, CFO of Nuvalent, executed 8 separate sales totaling 20,729 shares for $2,065,030.33 over two days, reducing her holdings from 82,463 to 61,734 shares (a 25.1% reduction). The blended average price of $99.62 sits below the current stock price of $107.13, meaning this disposal occurred before recent gains; the stock has rallied +9.4% over 30 days and +45.5% over 90 days. Notably, the company reported net income of -$122,437,000 and remains unprofitable, adding a material context to large insider dispositions. The CFO's prior 5 trades at NUVL (all in October 2025) showed positive 30-day returns ranging from +6.5% to +10.4%, yet this new multi-transaction filing represents a significantly larger liquidation and suggests a different magnitude of portfolio adjustment than those recent, smaller sales.

CFO Balcom sold 40,000 shares (39.3% of holdings) for $3.5M over two days; prior sales at NUVL warrant close monitoring.

Balcom Alexandra, CFO of Nuvalent, Inc., executed 7 separate sales totaling 40,000 shares for $3,494,303.10 on October 13–14, 2025, reducing holdings from 101,734 to 61,734 shares (39.3% reduction). The blended average sale price was $87.36, slightly below the current price of $89.64 but well within the 52-week range. This large reduction in CFO equity stake, combined with four other sales at NUVL in late September and early October 2025 (outcomes not yet measurable), suggests a sustained pattern of exit activity over a compressed timeframe. Notably, the company is unprofitable (net income of $-99,653,000.00 over its most recent full fiscal year), which adds context to concentrated insider liquidation at levels approaching the 52-week high. The proximity to recent highs and the magnitude of the stake reduction warrant investor attention to quarterly guidance and cash-burn outlook.

CFO Balcom sells 20,000 NUVL shares for $1.7M; company unprofitable with -$99.7M net loss

Balcom Alexandra, Chief Financial Officer of Nuvalent, Inc., executed 2 separate sales totaling 20,000 shares for $1,709,511.80 on 2025-10-01, reducing her holdings by 24.5% from 81,734 to 61,734 shares. The company reported a net loss of $-99,653,000.00 with a market cap of $263,556,720.48, indicating unprofitability over the most recent fiscal year. Her prior trades at NUVL show a pattern of recent selling activity (3 trades in July, 2 trades in late September), with measurable 30-day outcomes ranging from -10.6% to -7.1%, though no 90-day outcomes are yet measurable at this ticker. Across her broader cross-ticker track record, her sells have demonstrated an 84.62% well-timed rate over 90 days with an average 90-day return of -8.9%, indicating her prior sales have generally preceded stock declines, though this particular ticker shows an incomplete pattern.

CFO Balcom sells 27,588 shares for $2,346,255.88 at $85.05 avg; stock now $82.58; -30.9% of holdings.

Balcom Alexandra, CFO of Nuvalent Inc., executed two separate sales totaling 27,588 shares for $2,346,255.88 on 2025-09-29 and 2025-09-30, reducing holdings by -30.9% to 61,734 shares remaining. The blended average sale price of $85.05 sits 3.0% above the current price of $82.58, and the stock has declined -21.3% from its 52-week high of $104.93, placing the transaction near recent resistance. The company reported a net loss of $-99,653,000.00 over its most recent full fiscal year, a critical context given that the CFO is disposing of a material stake. While Balcom's cross-ticker track record shows a 90d well-timed sell rate of 84.62%, her prior trades specifically at NUVL have not yet demonstrated measurable 90-day outcomes that would support a timing signal on this transaction; the most recent same-ticker sales (2025-07-15 and 2025-07-16) showed 30-day declines of -7.1% and -8.4% respectively, which would be consistent with well-timed sells if the 90-day pattern holds, but the sample at this ticker remains incomplete.